January 19, 2021 -- Cure Genetics will collaborate with Boehringer Ingelheim to develop novel adeno-associated virus (AAV) vectors leveraging Cure Genetics' proprietary Velp platform to develop next-generation gene therapies.
The new collaboration will combine Boehringer Ingelheim's expertise in disease biology and gene therapy with Cure Genetics' AAV expertise in library construction and in vivo AAV screening. The goal is to provide potential new AAV serotypes for patients.
Cure Genetics' Velp platform includes a comprehensive strategy of engineering a plasmid library with high complexity and an effective ratio for optimized AAV production. The platform provides high genome-capsid correspondence and production capacity. It also enables significantly shorter process to find the "right" AAV vectors.
Boehringer Ingelheim aims to develop next-generation gene therapy focused under its Research Beyond Borders team.
The collaboration was initiated by the Boehringer Ingelheim China External Innovation Hub, which is committed to becoming the preferred partner of China's biopharmaceutical industry and bringing more Chinese innovative partnerships to enrich Boehringer Ingelheim's global research and development pipeline.